This information collectively suggests that metabolic comorbidities like obesity and diabetes, which are highly correlated with NAFLD, are not the primary drivers of the observed CYP2C19 downregulation. This evidence concerns the gene CYP2C19 and obesity due to melanocortin 4 receptor deficiency.